PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation
- 10 December 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (4) , 1246-1255
Abstract
Organ transplantation has been employed upon serious injuries, but a T-cell-mediated potent inflammatory immune response often leads to graft rejection. Immunosuppressive drugs such as rapamycin (RAPA) have to be taken after organ transplantation, but long-term use of these drugs causes severe adverse effects. Immune checkpoint pathways such as the programmed death-receptor 1/programmed death-ligand 1 (PD-1/PD-L1) provides an immunosuppressive environment, preventing excessive tissue destruction due to inflammatory immune responses. In this study, we bioengineered cell membrane-derived PD-L1 nanovesicles (PD-L1 NVs) to carry low doses of RAPA. These NVs inhibited T-cell activation and proliferation in vitro, by enhancing the PD-1/PD-L1 immune co-inhibitory signaling axis and inhibiting the mTOR pathway. Importantly, PD-L1 NVs encapsulated with rapamycin exerted stronger effects on inhibiting T-cell proliferation than PD-L1 NVs or rapamycin alone. This can be recapitulated in a mouse skin transplantation model, leading to the weakened alloimmune response and allograft tolerance. We also found that PD-L1/rapamycin vesicles have additional function to induce regulatory T cells in the recipient spleens. Our study highlighted the power of combining low-dose rapamycin and PD-L1 in the nanovesicles as immunosuppressants to promote allograft acceptance.Keywords
Funding Information
- National Natural Science Foundation of China (81702750)
- National Natural Science Foundation of China (81670141)
- National Natural Science Foundation of China (81970145)
- National Natural Science Foundation of China (82001698)
- Natural Science Foundation of Guangdong Province (2020A151501467)
- Natural Science Foundation of Guangdong Province (2020A1515011465)
- Medical Science and Technology Foundation of Guangdong Province (A2018320)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20170818164756460)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20180307154700308)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20170818163844015)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20180307151420045)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20190807151609464)
- Sun Yat-sen University (20ykzd17)
- Sun Yat-sen University (20ykpy122)
This publication has 36 references indexed in Scilit:
- Overview of Immunosuppressive Therapy in Solid Organ TransplantationAnesthesiology Clinics, 2017
- The mechanisms of rejection in solid organ transplantationTransfusion and Apheresis Science, 2017
- SnapShot: Immune Checkpoint InhibitorsCancer Cell, 2017
- Advances in diagnostics for transplant rejectionExpert Review of Molecular Diagnostics, 2016
- Current methods of the analysis of immunosuppressive agents in clinical materials: A reviewJournal of Pharmaceutical and Biomedical Analysis, 2016
- Immunosuppressive MedicationsClinical Journal of the American Society of Nephrology, 2016
- Immune Checkpoint Inhibitors2015
- Imaging transplant rejection: a new viewNature Medicine, 2011
- Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune ResponsesTransplantation, 2007
- Organ transplantation—how much of the promise has been realized?Nature Medicine, 2005